FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.
What happened
FDA inspected the Turkish drug manufacturing facility from May 6 to 10, 2024. FDA found that MedOffice did not test each batch of its over-the-counter drug products, including creams, for identity and strength of active ingredients before release, and did not adequately test for harmful microorganisms; some products had multiple complaints of microbial contamination. FDA also found that the firm skipped identity testing on incoming components, relied on supplier certificates without validating them, and did not adequately validate manufacturing processes, qualify equipment, or validate cleaning.
What FDA found
MedOffice did not test each batch of its drug products before release for identity and strength of each active ingredient and did not test as needed to show the products were free of harmful microorganisms.
21 CFR 211.165(a) and 211.165(b)MedOffice did not perform at least one identity test on each incoming component and did not validate the reliability of its suppliers’ test results at appropriate intervals.
21 CFR 211.84(d)(1) and 211.84(d)(2)MedOffice did not have adequate written production and process control procedures, and its quality control unit did not review and approve those procedures, including changes.
21 CFR 211.100(a)MedOffice did not adequately validate its manufacturing processes or qualify the equipment used to make its drug products.
21 CFR 211.100(a)MedOffice did not show that its cleaning procedure adequately cleans each type of equipment, including filling equipment shared with non-drug products.
21 CFR 211.100(a)
What FDA wants
FDA asks MedOffice to reply in writing within 15 working days describing what it has done to correct the violations and prevent recurrence, with detailed plans and records for release testing, supplier qualification, process validation, and cleaning validation. FDA also recommends that the firm engage a qualified consultant to audit its operations for drug manufacturing compliance.
Who should pay attention
- brands and distributors that buy over-the-counter drugs from this manufacturer
- US importers and private-label sellers of Turkish drug products
- manufacturers sharing filling equipment between drugs and non-drug products
This is a summary. Read the original letter on fda.gov.